Biosurfactant derived from probiotic Lactobacillus acidophilus exhibits broad-spectrum antibiofilm activity and inhibits the quorum sensing-regulated virulence.


Journal

Biomolecules & biomedicine
ISSN: 2831-090X
Titre abrégé: Biomol Biomed
Pays: Bosnia and Herzegovina
ID NLM: 9918522188506676

Informations de publication

Date de publication:
03 Nov 2023
Historique:
received: 29 05 2023
accepted: 30 06 2023
medline: 8 11 2023
pubmed: 8 7 2023
entrez: 8 7 2023
Statut: epublish

Résumé

Antimicrobial resistance by pathogenic bacteria has become a global risk to human health in recent years. The most promising approach to combating antimicrobial resistance is to target virulent traits of bacteria. In the present study, a biosurfactant derived from the probiotic strain Lactobacillus acidophilus was tested against three Gram-negative bacteria to evaluate its inhibitory potential on their biofilms, and whether it affected the virulence factors controlled by quorum sensing (QS). A reduction in the virulence factors of Chromobacterium violaceum (violacein production), Serratia marcescens (prodigiosin production) and Pseudomonas aeruginosa (pyocyanin, total protease, LasB elastase and LasA protease production) was observed at different sub-MIC concentrations in a dose-dependent manner. Biofilm development was reduced by 65.76%, 70.64% and 58.12% at the highest sub-MIC levels for C. violaceum, P. aeruginosa and S. marcescens, respectively. Biofilm formation on glass surfaces exhibited significant reduction, with less bacterial aggregation and reduced formation of extracellular polymeric materials. Additionally, swimming motility and exopolysaccharides (EPS) production were shown to be reduced in the presence of the L. acidophilus-derived biosurfactant. Furthermore, molecular docking analysis performed on compounds identified through gas chromatography-mass spectrometry (GC-MS) analysis of QS and biofilm proteins yielded further insights into the mechanism underlying the anti-QS activity. Therefore, the present study has clearly demonstrated that a biosurfactant derived from L. acidophilus can significantly inhibit virulence factors of Gram-negative pathogenic bacteria. This could provide an effective method to inhibit the formation of biofilms and QS in Gram-negative bacteria.

Identifiants

pubmed: 37421468
doi: 10.17305/bb.2023.9324
pmc: PMC10655870
doi:

Substances chimiques

Anti-Bacterial Agents 0
Virulence Factors 0
Peptide Hydrolases EC 3.4.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1051-1068

Références

Microb Pathog. 2018 Aug;121:190-197
pubmed: 29807134
Antimicrob Agents Chemother. 2008 Jan;52(1):198-203
pubmed: 17938186
Fitoterapia. 2013 Oct;90:73-8
pubmed: 23831483
Cold Spring Harb Perspect Med. 2012 Nov 01;2(11):
pubmed: 23125205
Antibiotics (Basel). 2021 Nov 09;10(11):
pubmed: 34827310
Food Sci Biotechnol. 2018 Apr 10;27(4):1137-1144
pubmed: 30263844
Appl Biochem Biotechnol. 2009 Sep;158(3):694-705
pubmed: 18716921
Front Microbiol. 2018 Jun 15;9:1241
pubmed: 29963020
Adv Colloid Interface Sci. 2020 Jan;275:102061
pubmed: 31767119
Appl Microbiol Biotechnol. 2019 Apr;103(8):3521-3535
pubmed: 30852658
Colloids Surf B Biointerfaces. 2017 Jul 1;155:522-529
pubmed: 28494430
Infect Drug Resist. 2020 Feb 26;13:659-672
pubmed: 32161474
Probiotics Antimicrob Proteins. 2019 Dec;11(4):1110-1123
pubmed: 30523603
Antimicrob Agents Chemother. 2011 Jun;55(6):2670-8
pubmed: 21444693
J Bacteriol. 2015 May;197(10):1716-25
pubmed: 25733618
Genome Announc. 2017 Sep 7;5(36):
pubmed: 28883127
Microorganisms. 2022 May 13;10(5):
pubmed: 35630468
Mol Microbiol. 1999 Nov;34(3):586-95
pubmed: 10564499
J Antibiot (Tokyo). 1999 Jul;52(7):613-9
pubmed: 10513840
Mol Microbiol. 2003 Jan;47(2):303-20
pubmed: 12519208
Pathogens. 2022 Feb 27;11(3):
pubmed: 35335624
Trends Microbiol. 2020 Sep;28(9):753-768
pubmed: 32359781
Chin Med. 2019 Mar 20;14:11
pubmed: 30936939
Chembiochem. 2011 Dec 16;12(18):2759-66
pubmed: 22045628
J Biol Chem. 1993 Apr 5;268(10):7503-8
pubmed: 8463280
Appl Microbiol Biotechnol. 2000 May;53(5):495-508
pubmed: 10855707
Anaerobe. 2011 Dec;17(6):280-5
pubmed: 21497662
Polym Bull (Berl). 2023;80(1):241-262
pubmed: 35125574
Crit Rev Biotechnol. 2010 Jun;30(2):127-44
pubmed: 20210700
Antimicrob Agents Chemother. 1972 Jul;2(1):23-8
pubmed: 4670656
J Cell Mol Med. 2018 Mar;22(3):1972-1983
pubmed: 29316223
J Biol Chem. 2011 Aug 12;286(32):28644-55
pubmed: 21673111
Front Microbiol. 2014 Oct 20;5:551
pubmed: 25368610
Curr Protoc Bioinformatics. 2008 Dec;Chapter 8:Unit 8.14
pubmed: 19085980
Trends Biotechnol. 2004 Mar;22(3):142-6
pubmed: 15036865
Chemotherapy. 2010;56(4):333-9
pubmed: 20720417
Microbiology (Reading). 2007 Dec;153(Pt 12):3923-3938
pubmed: 18048907
ACS Infect Dis. 2022 May 13;8(5):1010-1021
pubmed: 35451824
Antibiotics (Basel). 2021 Dec 17;10(12):
pubmed: 34943758
Food Chem. 2014 Apr 1;148:453-60
pubmed: 24262582
Int J Mol Sci. 2016 Mar 18;17(3):401
pubmed: 26999123
Appl Environ Microbiol. 2019 Apr 4;85(8):
pubmed: 30770405
Molecules. 2016 Apr 29;21(5):
pubmed: 27136524
Sci Rep. 2019 Mar 27;9(1):5287
pubmed: 30918296
BMC Genomics. 2007 Aug 22;8:287
pubmed: 17714587
Front Microbiol. 2020 May 13;11:823
pubmed: 32477292
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2860-5
pubmed: 20133655
J Bacteriol. 1990 Feb;172(2):884-900
pubmed: 2153661
Nat Rev Microbiol. 2011 Jan;9(1):27-38
pubmed: 21113182
J Pharm Anal. 2016 Apr;6(2):71-79
pubmed: 29403965
J Ethnopharmacol. 2014 May 28;154(1):170-5
pubmed: 24742751
Anat Rec. 1971 Nov;171(3):369-415
pubmed: 4108334
BMC Microbiol. 2016 Sep 17;16:216
pubmed: 27639378
Dent Res J (Isfahan). 2019 Mar-Apr;16(2):87-94
pubmed: 30820202
J Proteomics. 2019 Sep 30;208:103503
pubmed: 31454558
J Bacteriol. 2009 Mar;191(5):1393-403
pubmed: 19074399
Asian Pac J Trop Med. 2017 Aug;10(8):744-752
pubmed: 28942822
Microb Pathog. 2017 Mar;104:84-89
pubmed: 28087493
Mol Microbiol. 1998 Oct;30(2):285-93
pubmed: 9791174
Int J Mol Sci. 2018 Jan 10;19(1):
pubmed: 29320462
Appl Environ Microbiol. 2004 Mar;70(3):1593-9
pubmed: 15006783
Front Microbiol. 2016 Jun 10;7:863
pubmed: 27375584
Front Microbiol. 2015 Jun 09;6:577
pubmed: 26106379
Annu Rev Microbiol. 2003;57:677-701
pubmed: 14527295

Auteurs

Mohd Adnan (M)

Department of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.

Arif Jamal Siddiqui (AJ)

Department of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.

Emira Noumi (E)

Department of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.

Syed Amir Ashraf (SA)

Department of Clinical Nutrition, College of Applied Medial Sciences, University of Ha'il, Ha'il, Saudi Arabia.

Amir Mahgoub Awadelkareem (AM)

Department of Clinical Nutrition, College of Applied Medial Sciences, University of Ha'il, Ha'il, Saudi Arabia.

Sibte Hadi (S)

Department of Forensic Sciences, Naif Arab University for Security Sciences, Riyadh, Saudi Arabia.

Mejdi Snoussi (M)

Department of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.

Riadh Badraoui (R)

Department of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.

Fevzi Bardakci (F)

Department of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.

Manojkumar Sachidanandan (M)

Department of Oral Radiology, College of Dentistry, University of Ha'il, Ha'il, Saudi Arabia.

Mitesh Patel (M)

Department of Biotechnology, Parul Institute of Applied Sciences and Centre of Research for Development, Parul University, Vadodara, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH